COMMUNIQUÉS West-GlobeNewswire

The exercise period for warrants of series TO3 commences today
15/03/2024
Press Release Stockholm, Sweden, March 15, 2024 On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital raise of [...]
ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights
15/03/2024
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company expects to commercialize its ARC-EX ® System and commence the Empower BP [...]
ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing
15/03/2024
Erika Ross rejoint la société en tant que VP Global Clinical & Regulatory, et Sarah Moore au poste de VP Global Marketing EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 15 mars 2024 (GLOBE [...]
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
15/03/2024
Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Ibogaine By David Dardashti Explores Chemistry of Treatment for Long Term Opiate Abuse
15/03/2024
David Dardashti's Studies Reveal Powerful Effects of Pure Ibogaine Hydrochloride PLAYA DEL CARMEN, Mexico, March 14, 2024 (GLOBE NEWSWIRE) -- David Dardashti describes his discovery of ibogaine treatment for long term [...]
Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery
14/03/2024
BURR RIDGE, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology , the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT) for the [...]
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
14/03/2024
Anaphylm meets all predefined primary and secondary pharmacokinetic endpoints Anaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectors Anaphylm exposure levels (AUC) are comparable to [...]
Digicann Ventures Announces Granting of Forbearance for Convertible Debenture Maturity Date
14/03/2024
VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAF), a company focused on opportunities within and outside of the cannabis [...]
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
14/03/2024
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its [...]
BrightSpring Health Services’ Specialty Pharmacy Onco360® Celebrates Excellent Patient Care and Preferred Pharmacy Status
14/03/2024
LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company, Onco360 ® , one of the nation’s [...]
Onco360® Celebrates Excellent Patient Care, Reflected by Impressive Net Promoter Score
14/03/2024
LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- This year, Onco360 ® , the nation’s leading independent specialty oncology pharmacy, celebrates excellent service and care that resulted in unmatched patient [...]
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
14/03/2024
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein [...]
Intuitive Announces FDA Clearance of Fifth-Generation Robotic System, da Vinci 5
14/03/2024
Da Vinci 5 builds on decades of Intuitive technology and millions of robotic procedures SUNNYVALE, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive [...]
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
14/03/2024
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and [...]
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
14/03/2024
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for [...]
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
14/03/2024
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis [...]
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
14/03/2024
Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]
Un premier extrait de cannabis médical approuvé au Portugal pour Tilray Medical
14/03/2024
CANTANHEDE, Portugal, 14 mars 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., ci-après « Tilray » ou la « Société » (Nasdaq : TLRY ; TSX : TLRY), un producteur mondial de premier ordre spécialisé dans le cannabis et les [...]
TerrAscend Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Full year 2023 record Net Revenue of $317.3 million, an increase of 28.0% year-over-year Full year 2023 Gross Profit margin of 50.3%, a 930 basis-point improvement year-over-year Full year 2023 Adjusted EBITDA from [...]

Pages